Baker Jillian G, Hall Ian P, Hill Stephen J
Institute of Cell Signalling, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH.
Br J Pharmacol. 2002 Oct;137(3):400-8. doi: 10.1038/sj.bjp.0704855.
1 It has recently been reported that CGP 12177 can act as an agonist at a novel secondary site within the human beta(1)-adrenoceptor. The aim of this study was to undertake a detailed pharmacological study of the effects of CGP 12177 on the human beta(2)-adrenoceptor. 2 CGP 12177 acted as a potent partial agonist of (3)H-cyclic AMP accumulation (log EC(50)-8.90+/-0.06) and CRE-mediated reporter gene transcription (log EC(50)-9.66+/-0.04) in CHO-K1 cells expressing the human beta(2)-adrenoceptor. These CGP-induced responses were antagonized by the beta(2)-selective antagonist ICI 118551 (apparent log K(D) values of -8.84+/-0.15 and -9.51+/-0.02 for the cyclic AMP and reporter gene responses respectively). 3 CGP 12177 was also able to antagonize both cyclic AMP and reporter gene responses to more efficacious beta(2)-agonists with similar log K(D) values (e.g. -9.57+/-0.15 and -10.04+/-0.096 respectively with salbutamol as agonist). 4 (3)H-CGP 12177 binding to beta(2)-adrenoceptors in intact CHO-beta(2) cells yielded a log K(D) value of -9.84+/-0.06, but indicated that the ligand dissociates very slowly from the receptor (t(1/2) for dissociation=65 min). However, studies with a Green Fluorescent Protein (GFP)-tagged beta(2)-adrenoceptor indicated that CGP 12177 does not stimulate beta(2)-adrenoceptor internalization. 5 This study demonstrates that CGP 12177 is a high affinity partial agonist of both cAMP accumulation and CRE-mediated gene transcription at the human beta(2)-adrenoceptor. It provides no evidence that CGP 12177 can discriminate a secondary site on the beta(2)-adrenoceptor analogous to that observed for the human beta(1)-adrenoceptor. However, despite its very weak actions on cAMP accumulation, the potent agonist effects of CGP 12177 on CRE-mediated gene transcription at the human beta(2)-adrenoceptor, coupled with its long duration of action, offers a potential lead for drug development for the treatment of chronic inflammatory airway diseases.
最近有报道称,CGP 12177可作为人β1肾上腺素受体新的次要位点的激动剂。本研究的目的是对CGP 12177对人β2肾上腺素受体的作用进行详细的药理学研究。
在表达人β2肾上腺素受体的CHO-K1细胞中,CGP 12177作为(3)H-环磷酸腺苷积累(对数EC50 - 8.90±0.06)和CRE介导的报告基因转录(对数EC50 - 9.66±0.04)的强效部分激动剂。这些CGP诱导的反应被β2选择性拮抗剂ICI 118551拮抗(环磷酸腺苷和报告基因反应的表观对数KD值分别为-8.84±0.15和-9.51±0.02)。
CGP 12177还能够拮抗环磷酸腺苷和报告基因对更有效的β2激动剂的反应,其对数KD值相似(例如,以沙丁胺醇为激动剂时分别为-9.57±0.15和-10.04±0.096)。
(3)H-CGP 12177与完整的CHO-β2细胞中的β2肾上腺素受体结合,对数KD值为-9.84±0.06,但表明配体从受体解离非常缓慢(解离的t1/2 = 65分钟)。然而,对绿色荧光蛋白(GFP)标记的β2肾上腺素受体的研究表明,CGP 12177不会刺激β2肾上腺素受体内化。
本研究表明,CGP 12177是人β2肾上腺素受体上cAMP积累和CRE介导的基因转录的高亲和力部分激动剂。它没有提供证据表明CGP 12177可以区分β2肾上腺素受体上类似于人β1肾上腺素受体上观察到的次要位点。然而,尽管其对cAMP积累的作用非常微弱,但CGP 12177对人β2肾上腺素受体上CRE介导的基因转录的强效激动剂作用,加上其长效作用,为治疗慢性炎症性气道疾病的药物开发提供了潜在的先导化合物。